ReviewChest2016
Chronic Pulmonary Complications of Sickle Cell Disease.
Review in Chest, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.The Cochrane database of systematic reviews · 2019Pooled it
- Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.The Cochrane database of systematic reviews · 2016Pooled it
- Systematic Review of Extracorporeal Membrane Oxygenation in Adult Sickle Cell Disease.Journal of clinical medicine · 2025Review
- Targeting lung heme iron by aerosol hemopexin adminstration in sickle cell disease pulmonary hypertension.Free radical biology & medicine · 2025Article
- Respiratory phenotype and health care utilization patterns by adults with sickle cell disease.Blood advances · 2025Article
- Pulmonary Function after Nonmyeloablative Hematopoietic Cell Transplant for Sickle Cell Disease.Annals of the American Thoracic Society · 2024Article
- Prevalence, patterns, and factors associated with abnormal lung function among children with sickle cell disease in Uganda: a cross-sectional study.BMC pediatrics · 2024Article
- Haemolytic Anaemia-Related Pulmonary Hypertension.Life (Basel, Switzerland) · 2024Article
- Pulmonary Hypertension in Sickle Cell Disease: Novel Findings of Gene Polymorphisms Related to Pathophysiology.International journal of molecular sciences · 2024Review
- Article
- Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach.Journal of clinical medicine · 2023Review
- Review
- Sickle cell disease related chronic thromboembolic pulmonary hypertension: challenging clinical scenario.Journal of thrombosis and thrombolysis · 2022Article
- Point of care ultrasound detection of thrombus straddling a patent foramen ovale in a patient with acute chest syndrome.Respiratory medicine case reports · 2022Article
- Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease.European journal of haematology · 2021Article
- Sickle Cell Disease and the Respiratory System: A Tangential Perspective to the Hematopulmonological Dilemma.Cureus · 2021Review
- Pediatric thalassemic patients have higher incidence of asthma: A nationwide population-based retrospective cohort study.PloS one · 2021Article
- Management of chronic respiratory complications in children and adolescents with sickle cell disease.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Salbutamol Worsens the Autonomic Nervous System Dysfunction of Children With Sickle Cell Disease.Frontiers in physiology · 2020Article
- Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report.Annals of the American Thoracic Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Sickle cell disease (SCD), the most common genetic hemolytic anemia worldwide, affects 250,000 births annually. In the United States, SCD affects approximately 100,000 individuals, most of African descent. Hemoglobin S (HbS) results from a glutamate-to-valine mutation of the sixth codon of the β-hemoglobin allele; the homozygous genotype (HbSS) is associated with the most prevalent and severe form of the disease. Other SCD genotypes include HbSC, composed of one HbS allele and one HbC (glutamate-to-lysine mutation) allele; and HbS-β-thalassemia(0) or HbS-β-thalassemia(+), composed of one HbS allele and one β-thalassemia allele with absent or reduced β-chain production, respectively. Despite advances in care, median survival remains in the fifth decade, due in large part to chronic complications of the disease. Chronic pulmonary complications in SCD are major contributors to this early mortality. Although our understanding of these conditions has improved much over the past 10 to 15 years, there remains no specific treatment for pulmonary complications of SCD. It is unclear whether conventional treatment regimens directed at non-SCD populations have equivalent efficacy in patients with SCD. This represents a critical research need. In this review, the authors review the state-of-the-art understanding of the following pulmonary complications of SCD: (1) pulmonary hypertension; (2) venous thromboembolic disease; (3) sleep-disordered breathing; (4) asthma and recurrent wheezing; and (5) pulmonary function abnormalities. This review highlights the advances as well as the knowledge gaps in this field to update clinicians and other health care providers and to garner research interest from the medical community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.